Lifileucel versus Nivolumab plus Ipilimumab (NIVO+IPI) in anti-PD1 resistant advanced melanoma: An Indirect Comparison of Objective Response Rates (ORRs) between C-144-01 and SWOG-S1616 (ESMO-IO 2026) - Oct 25, 2026 - Abstract #116P; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Clinical • Metastases • Melanoma • Oncology • Solid Tumor
|
|
Daniel O lson; Oguzhan Alagoz; Murat Kurt; Christoffer Gebhardt; Josh Wang; Martijn S. Bijker; Bria n Gastman; Yan Xing; Paolo A. Ascierto
|